新诺威：筹划发行H股股票并在香港联交所上市

Core Viewpoint - The company plans to apply for an initial public offering (IPO) of overseas listed shares (H-shares) to enhance its global strategy, improve international market competitiveness, and promote the development of its pharmaceutical business [1] Group 1: IPO Plans - The company aims to create an international capital operation platform through the proposed H-share IPO [1] - The IPO will be submitted for approval at a shareholders' meeting and requires regulatory approvals from relevant government and regulatory bodies [1] - The company will consider the interests of existing shareholders and market conditions to choose an appropriate timing for the H-share issuance and listing [1] Group 2: Uncertainties and Disclosure - Specific details regarding the IPO are not yet finalized, indicating significant uncertainties surrounding the matter [1] - The company commits to fulfilling its information disclosure obligations as the situation develops [1]